A method for making an alkyl cyclobutane fuel, which includes obtaining a solution of at least one alpha olefin. A catalyst is added to the solution, thereby generating a mixture of dimers. The mixture is hydrogenated, thereby converting the dimers to hydrogenated dimers. The mixture is purified to produce an alkyl cyclobutane fuel.

Provided is a separation membrane that is suitable for use in separating one or more hydrocarbons from a hydrocarbon mixture. More specifically, the separation membrane includes a porous support for which acid content is not substantially detected by ammonia temperature programmed desorption in a temperature range of higher than 450 C. and not higher than 600 C. and a porous separation layer containing a zeolite that is disposed on the porous support.

Provided is a separation membrane that is suitable for use in separating one or more hydrocarbons from a hydrocarbon mixture. More specifically, the separation membrane includes a porous support for which acid content is not substantially detected by ammonia temperature programmed desorption in a temperature range of higher than 450 C. and not higher than 600 C. and a porous separation layer containing a zeolite that is disposed on the porous support.

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them.

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them.

Provided herein are Purine Compounds of Formula (I)

##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

This invention relates to the field of polymers and olefin polymerization, and more specifically olefin metathesis polymerization. Specifically, the present invention provides a polymer comprising rigorously alternating AB subunits and methods of formation of the AB alternating polymers. In the polymers and process of the invention, the A monomer is derived from a cyclobutene derivative, and the B monomer is derived from a cyclohexene derivative. The polymerization takes place in the presence of an olefin metathesis catalyst.

This invention relates to the field of polymers and olefin polymerization, and more specifically olefin metathesis polymerization. Specifically, the present invention provides a polymer comprising rigorously alternating AB subunits and methods of formation of the AB alternating polymers. In the polymers and process of the invention, the A monomer is derived from a cyclobutene derivative, and the B monomer is derived from a cyclohexene derivative. The polymerization takes place in the presence of an olefin metathesis catalyst.

Provided herein are Purine Compounds of Formula (I) ##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologs, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

Provided herein are Purine Compounds of Formula (I) ##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologs, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.